Heart device aims to cut stroke risk without lifelong pills

NCT ID NCT04684212

Terminated Disease control Sponsor: Brian O'Neill MD Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study was designed to test a device called LAmbre Plus, which is implanted to seal off a small pouch in the heart where clots can form in people with atrial fibrillation. The goal was to see if it could safely prevent strokes in patients with large or irregularly shaped heart pouches who are at high risk. However, the trial was withdrawn before any participants were enrolled, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LAmbre Plus Left Atrial Appendage Closure System (a device implanted to seal off part of the heart)
What this could lead to: If successful, this device could offer a stroke-prevention option for people with atrial fibrillation who cannot take blood thinners long-term.
What could go wrong: The trial was withdrawn before enrolling anyone, so no data exists. Device procedures carry risks like bleeding, heart perforation, or device movement.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation stroke disorder Thromboembolism thrombotic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATRIAL FIBRILLATION CVA LEFT ATRIAL APPENDAGE THROMBOSIS

Contacts and locations

Locations

Henry Ford Hospital

Detroit, Michigan, 48202, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.